Miguel Reyes-Múgica

Miguel Reyes-Múgica

Auto-generated profile, based on publicly available information

Miguel Reyes-Múgica

Department of Pathology and Laboratory Medicine, University of Miami Miller School of Medicine, 1611 NW 12th Avenue, Holtz Center, Room 2147, Miami, FL, 33125, USA.

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 December 2021 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
Stefan PfisterStefan Pfister
Stefan Pfister
MRMiguel Reyes-Múgica
Miguel Reyes-Múgica
JCJohn K.C. Chan
John K.C. Chan
HHHenrik Hasle
Henrik Hasle
ALAlexander J. Lazar
Alexander J. Lazar
RARita Alaggio
Rita Alaggio
Pediatric tumors are uncommon, yet are the leading cause of cancer-related death in childhood. Tumor types, molecular characteristics, and pathogenesis are unique, often originating from a single genetic driver event. The specific diagnostic challenges of childhood tumors led to the development of the first World Health Organization (WHO) Classification of Pediatric Tumors. The classification is rooted in a multilayered approach, incorporating morphology, IHC, and molecular characteristics. The volume is organized according to organ sites and provides a single, state-of-the-art compendium of pediatric tumor types. A special emphasis was placed on “blastomas,” which variably recapitulate the morphologic maturation of organs from which they originate. Significance: In this review, we briefly summarize the main features and updates of each chapter of the inaugural WHO Classification of Pediatric Tumors, including its rapid transition from a mostly microscopic into a molecularly driven classification systematically taking recent discoveries in pediatric tumor genomics into account.

9 October 2019 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
HLHonghai Liu
Honghai Liu
CZCheng-Hai Zhang
Cheng-Hai Zhang
NANiyatie Ammanamanchi
Niyatie Ammanamanchi
SSSangita Suresh
Sangita Suresh
CLChristopher Lewarchik
Christopher Lewarchik
BKBernhard Kühn
Bernhard Kühn
Control of cytokinesis by β-adrenergic receptors indicates an approach for regulating the established number of cardiomyocytes.

1 January 2015 in Pediatric and Developmental Pathology
Verified
Journal Article
Open access
CSClaudia M Salgado
Claudia M Salgado
DBDipanjan Basu
Dipanjan Basu
MNMarina Nikiforova
Marina Nikiforova
BBBruce S. Bauer
Bruce S. Bauer
DJDonald Johnson
Donald Johnson
MRMiguel Reyes-Múgica
Miguel Reyes-Múgica
NRAS and BRAF mutations occur in congenital melanocytic nevi (CMN), but results are contradictory. Sixty-six prospectively collected CMN patients were analyzed for NRAS Q61 mutations using Sanger sequencing. Negative cases were evaluated for BRAF V600E mutation. NRAS Q61 mutations affected 51 patients (77.3%), and BRAF V600E was found in 5 (7.6%). NRAS Q61 mutation affected 29 (80.6%) of 36 giant, 16 (80.0%) of 20 large, and 5 (62.5%) of 8 medium-size CMN; BRAF mutation affected 1 (5%) of 20 large and 4 (11.4%) of 36 giant CMN. Compared to NRAS, BRAF-mutated nevi show scattered/extensive dermal and subcutaneous nodules (100% BRAF+ vs 34.8% NRAS+) ( P = 0.002). Neurocutaneous melanocytosis (NCM) affected 16 (24.2%) of 66 patients, with NRAS Q61 mutation in 12 (75.0%), and BRAF V600E in 2 (12.5%), P = 0.009. Two patients were negative for both mutations (12.5%). In conclusion, although NRAS Q61 mutations predominate, BRAF V600E mutation also affects patients with large/giant CMN (L/GCMN), and with NCM, a novel finding. BRAF V600E is also associated with increased dermal/subcutaneous nodules. These findings open the possibility of BRAF-targeted therapy in some L/GCMN and NCM cases.

28 March 2011 in Cancer
Verified
Journal Article
Open access
PDF file
JPJennifer Picarsic
Jennifer Picarsic
RJRonald Jaffe
Ronald Jaffe
GMGeorge Mazariegos
George Mazariegos
SWSteve A. Webber
Steve A. Webber
DEDemetrius Ellis
Demetrius Ellis
MRMiguel Reyes‐Múgica
Miguel Reyes‐Múgica
BACKGROUND: Although the literature reports a low incidence of Burkitt lymphoma (BL) as a post‐transplant lymphoproliferative disorder (PTLD), this entity appears to be different from other monomorphic PTLDs (M‐PTLDs), both in its aggressive clinical presentation and its distinct pathologic profile.METHODS: Patients with BL, diagnosed in the post‐transplant setting, (patients aged ≤18 years) were retrieved from the pathology archives at Children's Hospital of Pittsburgh of the University of Pittsburgh Medical Center from 1982 to 2010. Clinical outcomes were obtained along with pathologic review.RESULTS: Twelve patients with pediatric BL in the post‐transplant setting (9 boys, 3 girls) were retrieved. The patients displayed a monomorphic population of small to intermediate‐sized, noncleaved, lymphoid elements with a “starry‐sky” pattern. The immunophenotype for patients available to the study was CD20+ (n = 9/10), CD10+ (n = 8/8), bcl‐6+ (n = 11/11), with a near 100% Ki‐67/MIB‐1 proliferation index (n = 7/7), and negative for TdT (n = 7/7). Most pretransplant Epstein‐Barr virus titers were negative (n = 8/10), with post‐transplant titers positive in all tested patients (n = 11), and with positive Epstein‐Barr–encoded RNA in situ hybridization in most cases (n = 9/11). The median time from transplantation to diagnosis was 52 months (range, 6‐107 months). Nine patients were currently alive after immediate antineoplastic chemotherapy, with median disease‐free time of 93 months from diagnosis (range, 2‐199 months).CONCLUSIONS: BL‐PTLD had a higher Epstein‐Barr virus incidence compared with sporadic and immunodeficiency‐associated BL and represented a distinct monomorphic PTLD. Although some M‐PTLDs can be managed less aggressively with decreased immunosuppression alone, immediate lymphoma‐specific chemotherapy was associated with a favorable outcome and was strongly recommended. Cancer 2011;. © 2011 American Cancer Society.

10 August 2023 in Journal of Hepatology
Verified
Journal Article
Open access
JGJoseph Glessner
Joseph Glessner
MNMylarappa B. Ningappa
Mylarappa B. Ningappa
KNKim A. Ngo
Kim A. Ngo
MZMaliha Zahid
Maliha Zahid
JSJuhoon So
Juhoon So
RSRakesh K. Sindhi
Rakesh K. Sindhi
Biliary atresia (BA) is poorly understood and leads to liver transplantation (LT), with the requirement for and associated risks of lifelong immunosuppression, in most children. We performed a genome-wide association study (GWAS) to determine the genetic basis of BA. We performed a GWAS in 811 European BA cases treated with LT in US, Canadian and UK centers, and 4,654 genetically matched controls. Whole-genome sequencing of 100 cases evaluated synthetic association with rare variants. Functional studies included whole liver transcriptome analysis of 64 BA cases and perturbations in experimental models. A GWAS of common single nucleotide polymorphisms (SNPs), i.e. allele frequencies >1%, identified intronic SNPs rs6446628 in AFAP1 with genome-wide significance (p = 3.93E-8) and rs34599046 in TUSC3 at sub-threshold genome-wide significance (p = 1.34E-7), both supported by credible peaks of neighboring SNPs. Like other previously reported BA-associated genes, AFAP1 and TUSC3 are ciliogenesis and planar polarity effectors (CPLANE). In gene-set-based GWAS, BA was associated with 6,005 SNPs in 102 CPLANE genes (p = 5.84E-15). Compared with non-CPLANE genes, more CPLANE genes harbored rare variants (allele frequency <1%) that were assigned Human Phenotype Ontology terms related to hepatobiliary anomalies by predictive algorithms, 87% vs. 40%, p <0.0001. Rare variants were present in multiple genes distinct from those with BA-associated common variants in most BA cases. AFAP1 and TUSC3 knockdown blocked ciliogenesis in mouse tracheal cells. Inhibition of ciliogenesis caused biliary dysgenesis in zebrafish. AFAP1 and TUSC3 were expressed in fetal liver organoids, as well as fetal and BA livers, but not in normal or disease-control livers. Integrative analysis of BA-associated variants and liver transcripts revealed abnormal vasculogenesis and epithelial tube formation, explaining portal vein anomalies that co-exist with BA. BA is associated with polygenic susceptibility in CPLANE genes. Rare variants contribute to polygenic risk in vulnerable pathways via unique genes. Liver transplantation is needed to cure most children born with biliary atresia, a poorly understood rare disease. Transplant immunosuppression increases the likelihood of life-threatening infections and cancers. To improve care by preventing this disease and its progression to transplantation, we examined its genetic basis. We find that this disease is associated with both common and rare mutations in highly specialized genes which maintain normal communication and movement of cells, and their organization into bile ducts and blood vessels during early development of the human embryo. Because defects in these genes also cause other birth defects, our findings could lead to preventive strategies to lower the incidence of biliary atresia and potentially other birth defects.

7 February 2022 in Paediatric Respiratory Reviews
Verified
Journal Article
Closed access
FFFrances Flanagan
Frances Flanagan
ACAlicia Casey
Alicia Casey
MRMiguel Reyes-Múgica
Miguel Reyes-Múgica
GKGeoffrey Kurland
Geoffrey Kurland